When the pivotal ATLAS ACS 2-TIMI 51 trial was unveiled in 2011 it was widely praised.
FORBES: FDA Again Rejects ACS Indication for Rivaroxaban (Xarelto)
应用推荐
模块上移
模块下移
不移动